eFFECTOR Therapeutics Appoints Douglas Warner, M.D., as Chief Medical Officer
08 Août 2022 - 11:30AM
eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the
development of selective translation regulator inhibitors (“STRIs”)
for the treatment of cancer, today announced it has appointed
Douglas Warner, M.D., as chief medical officer. Dr. Warner will
develop strategies to continue advancing eFFECTOR’s two
clinical-stage STRIs into advanced and potentially registrational
trials.
“Dr. Warner has extensive experience in oncology therapeutic
development, and his expertise designing and executing clinical
trials across all developmental stages, especially Phase 3, will be
invaluable as we continue to advance our pipeline in a range of
cancers,” said Steve Worland, Ph.D., president and chief executive
officer of eFFECTOR. “We are very excited to welcome him to the
team. We also want to thank our senior clinical development
advisor, Dr. Bob Sikorski, who has provided exceptional work
ensuring the smooth advancement of all our trials as we conducted
the search for a new CMO and who will continue to work closely in
an advisory role.”
Dr. Warner will be responsible for overseeing eFFECTOR’s ongoing
clinical trials, including its KICKSTART Phase 2b trial of
tomivosertib in combination with pembrolizumab in non-small cell
lung cancer, its Phase 1/2 study of zotatifin in oncology and its
Phase 1 study of zotatifin in COVID-19. He will also be responsible
for developing registration strategies for both programs and
exploring expansion into additional oncology indications.
“I appreciate the vision that eFFECTOR has for oncology drug
development as well as the company’s commitment to discovering and
developing an entirely new class of medicines that has the
potential to overcome tumors’ mechanisms of resistance,” Dr. Warner
said. “The data from early trials are compelling, and I’m eager to
steer future development for our two clinical compounds.”
Prior to eFFECTOR, Dr. Warner held roles of increasing
responsibility over 18 years at Amgen where he oversaw extensive
clinical development programs in multiple indications across
oncology and general medicine. In his most recent position,
Executive Medical Director, Group Product Area Lead, Dr. Warner
provided development guidance and oversight over a broad portfolio
of solid tumor immune-oncology and pathway inhibitor development
programs that ranged from phase 1 to marketed products. Prior to
this position, Dr. Warner was the Global Development Lead for
several products including Vectibix®, XGEVA®, and
Prolia®. In this role, Dr. Warner led evidence
generation and oversaw the design, execution, and analysis of
studies across the phases of development, including large global
phase 3 trials, and was the clinical development leader for major
regulatory filings worldwide. Dr. Warner is co-author on numerous
peer-reviewed articles including those in The Lancet, The Lancet
Oncology, and The Journal of Clinical Oncology. He received his
B.A. from the University of Pennsylvania, his M.D. from the Duke
University School of Medicine, and his M.B.A. from the UCLA
Anderson School of Management.
About eFFECTOR TherapeuticseFFECTOR is a
clinical-stage biopharmaceutical company pioneering the development
of a new class of oncology drugs referred to as STRIs. eFFECTOR’s
STRI product candidates target the eIF4F complex and its activating
kinase, mitogen-activated protein kinase interacting kinase (MNK).
The eIF4F complex is a central node where two of the most
frequently mutated signaling pathways in cancer, the PI3K-AKT and
RAS-MEK pathways, converge to activate the translation of select
mRNA into proteins that are frequent culprits in key
disease-driving processes. Each of eFFECTOR’s product candidates is
designed to act on a single protein that drives the expression of a
network of functionally related proteins, including oncoproteins
and immunosuppressive proteins in T cells, that together control
tumor growth, survival and immune evasion. eFFECTOR’s lead product
candidate, tomivosertib, is a MNK inhibitor currently being
evaluated in KICKSTART, a randomized, double-blind,
placebo-controlled Phase 2b trial of tomivosertib in combination
with pembrolizumab in patients with metastatic non-small cell lung
cancer (NSCLC). Zotatifin, eFFECTOR’s inhibitor of eIF4A, is
currently being evaluated in Phase 2a expansion cohorts in certain
biomarker-positive solid tumors, including ER+ breast cancer and
KRAS-mutant NSCLC. eFFECTOR has a global collaboration with Pfizer
to develop inhibitors of a third target, eIF4E. In addition to the
company’s oncology focus, zotatifin is being evaluated as a
potential host-directed anti-viral therapy in patients with mild to
moderate COVID-19 in collaboration with the University of
California, San Francisco, under a $5 million grant sponsored by
the Defense Advanced Research Projects Agency.
Forward-Looking Statements
eFFECTOR cautions you that statements contained in this press
release regarding matters that are not historical facts are
forward-looking statements. The forward-looking statements are
based on our current beliefs and expectations and include, but are
not limited to, statements regarding: the future clinical
development of our product candidates, including potential
registrational clinical trials; and the potential therapeutic
benefits of our product candidates. Actual results may differ from
those set forth in this press release due to the risks and
uncertainties inherent in our business, including, without
limitation: potential delays in the commencement, enrollment and
completion of clinical trials; additional disruptions to our
operations from the COVID-19 pandemic, including clinical trial and
manufacturing delays; our dependence on third parties in connection
with product manufacturing, research and preclinical and clinical
testing; the results of preclinical studies and early clinical
trials are not necessarily predictive of future results; the
success of our clinical trials and preclinical studies for our
product candidates is uncertain; we may use our capital resources
sooner than expected and they may be insufficient to allow clinical
trial readouts; regulatory developments in the United States and
foreign countries; unexpected adverse side effects or inadequate
efficacy of our product candidates that may limit their
development, regulatory approval and/or commercialization, or may
result in recalls or product liability claims; our ability to
obtain and maintain intellectual property protection for our
product candidates; and other risks described in our prior filings
with the Securities and Exchange Commission. You are cautioned not
to place undue reliance on these forward-looking statements, which
speak only as of the date hereof, and we undertake no obligation to
update such statements to reflect events that occur or
circumstances that exist after the date hereof. All forward-looking
statements are qualified in their entirety by this cautionary
statement, which is made under the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995.
Contacts:Investors:Stephanie
CarringtonICR
Westwicke646-277-1282Stephanie.Carrington@westwicke.com
Media:Heidi Chokeir, Ph.D.Canale
Communications619-203-5391heidi.chokeir@canalecomm.com
Editors’ note: head shot available upon request
eFFECTOR Therapeutics (NASDAQ:EFTR)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
eFFECTOR Therapeutics (NASDAQ:EFTR)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024